Demographics of patients receiving TPOXX for treatment of monkeypox

Details

• Corporate Authors:
  National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of High-Consequence Pathogens and Pathology.
• Description:
  Updated November 16, 2022 ; TPOXX (tecovirimat) use for treatment of monkeypox is authorized under Food and Drug Administration (FDA) regulations, and CDC holds an expanded access Investigational New Drug (EA-IND) protocol. The IND forms are required to be submitted to CDC. The demographics of patients prescribed TPOXX treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who are receiving TPOXX treatment as healthcare providers can start treatment before submitting IND paperwork to CDC.
• Subjects:
  • Antiviral Agents
  • Drugs, Investigational
  • Mpox (monkeypox)
  • Poxviridae Infections/drug therapy
  • Smallpox/drug therapy
• Document Type:
  Webpage
• Corporate as Subject:
  Tecovirimat ; Tecovirimat
• Place as Subject:
  United States
• Download URL:
  https://stacks.cdc.gov/view/cdc/122263/cdc_122263_DS1.pdf
• File Type:
  [PDF - 1.46 MB]
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:24add1bf227a810662010be062d8b6fbf661f0ba50c71d74e2bb69a73e9b8b50